Ratings by Jefferies (Farzin Haque)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/30/2026 | Vor Biopharma, Inc. | VOR | Maintain | Buy (Buy) |
|
Details | ||
| 3/29/2026 | Vor Biopharma, Inc. | VOR | New Coverage | Buy (N/A) |
13.57 (19.80) |
45.91% | Details | |
| 3/23/2026 | Pyxis Oncology Inc. | PYXS | Maintain | Buy (N/A) |
|
Details | ||
| 12/22/2025 | Relmada Therapeutics Inc | RLMD | New Coverage | Buy (N/A) |
4.15 (3.51) |
-15.42% | Details | |
| 9/30/2025 | Nuvation Bio Inc | NUVB | New Coverage | Buy (N/A) |
3.20 (4.90) |
53.13% | Details | |
| 8/4/2025 | Werewolf Therapeutics Inc. | HOWL | New Coverage | Buy (N/A) |
1.21 (0.98) |
-19.01% | Details | |
| 3/18/2025 | Pyxis Oncology Inc. | PYXS | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2024 | Pyxis Oncology Inc. | PYXS | New Coverage | Buy (N/A) |
4.31 (2.01) |
-53.36% | Details |
